Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy

被引:6
|
作者
Kondo, Yasuteru [1 ]
Ueno, Yoshiyuki [1 ]
Ninomiya, Masashi [1 ]
Tamai, Keiichi [1 ]
Tanaka, Yasuhito [2 ]
Inoue, Jun [1 ]
Kakazu, Eiji [1 ]
Kobayashi, Koju
Kimura, Osamu [1 ]
Miura, Masahito [3 ]
Yamamoto, Takeshi [4 ]
Kobayashi, Tomoo [5 ]
Igarashi, Takehiko [6 ]
Shimosegawa, Tooru [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Div Gastroenterol, Aoba Ku, Sendai, Miyagi 980, Japan
[2] Nagoya City Univ, Sch Med, Virol & Liver Unit, Nagoya, Aichi 467, Japan
[3] S Miyagi Med Ctr, Dept Gastroenterol, Oogawara, Miyagi, Japan
[4] Tohoku Kosei Nenkin Hosp, Dept Gastroenterol, Sendai, Miyagi, Japan
[5] Tohoku Rosai Hosp, Dept Hepatol, Sendai, Miyagi, Japan
[6] Osaki Citizen Hosp, Dept Gastroenterol, Osaki, Japan
关键词
Dual infection; HBV; HCV; Immunopathogenesis; HEPATITIS-B-VIRUS; REGULATORY T-CELLS; HEPATOCELLULAR-CARCINOMA; COINFECTED PATIENTS; DUAL INFECTION; GENOTYPE-B; VIRAL INTERACTIONS; IMMUNE-RESPONSES; INTERFERON; RIBAVIRIN;
D O I
10.1007/s00535-012-0596-x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The immunopathogenesis of dual chronic infection with hepatitis B virus and hepatitis C virus (HBV/HCV) remains unclear. The in vivo suppressive effects of each virus on the other have been reported. In this study we aimed to analyze the virological and immunological parameters of HBV/HCV coinfected patients during pegylated interferon/ribavirin (Peg-IFN/RBV) therapy. One patient with high HBV-DNA and high HCV-RNA titers (HBV-high/HCV-high) and 5 patients with low HBV-DNA and high HCV-RNA titers (HBV-low/HCV-high) were enrolled. Twenty patients monoinfected with HBV and 10 patients monoinfected with HCV were enrolled as control subjects.. In vitro cultures of Huh 7 cells with HBV/HCV dual infection were used to analyze the direct interaction of HBV/HCV. Direct interaction of HBV clones and HCV could not be detected in the Huh-7 cells. In the HBV-high/HCV-high-patient, the HCV-RNA level gradually declined and HBV-DNA gradually increased during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased at 1 month of Peg-IFN/RBV-therapy, but HBV-specific IFN-gamma-secreting cells were not increased and HBV-specific interleukin (IL)-10 secreting cells were increased. The level of HBV- and HCV-specific IFN-gamma-secreting cells in the HBV-high/HCV-high-patient was low in comparison to that in the HBV- or HCV-monoinfected patients. In the HBV-low/HCV-high-patient, HCV-RNA and HBV-DNA rapidly declined during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased, and HBV- and HCV-specific IFN-gamma-secreting cells were also increased during Peg-IFN/RBV-therapy. The immunological responses of the HBV-high/HCV-high patient were low in comparison to the responses in HBV and HCV monoinfected patients. Moreover, the response of immune cells in the HBV-high/HCV-high patient during Peg-IFN/RBV therapy was insufficient to suppress HBV and HCV.
引用
收藏
页码:1323 / 1335
页数:13
相关论文
共 50 条
  • [21] ACCURATE INDIVIDUALIZATION OF PEG-IFN plus RBV TREATMENT DURATION BY HCV INFECTED CELL DECLINE COMPUTED IN THE 1ST MONTH OF THERAPY
    Colombatto, P.
    Romagnoli, V.
    Civitano, L.
    Ciccorossi, P.
    Maina, A. M.
    Oliveri, F.
    Coco, B.
    Cherubini, B.
    Bonino, F.
    Brunetto, M. R.
    DIGESTIVE AND LIVER DISEASE, 2010, 42 : S46 - S47
  • [22] Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV/HIV co-infected individuals
    Shea, D. O.
    Tuite, H.
    Farrell, G.
    Codd, M.
    Mulcahy, F.
    Norris, S.
    Bergin, C.
    JOURNAL OF VIRAL HEPATITIS, 2008, 15 (07) : 482 - 489
  • [23] Sustained virologic response (SVR) following interferon (IFN) and ribavirin (RBV) therapy for hepatitis C (HCV) patients who are co-infected with HIV
    Dieterich, DT
    Suciu, L
    Goldman, DJ
    Weisz, KB
    Jonea, J
    CLINICAL INFECTIOUS DISEASES, 2000, 31 (01) : 215 - 215
  • [24] ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type
    Matsuura, K.
    Tanaka, Y.
    Watanabe, T.
    Fujiwara, K.
    Orito, E.
    Kurosaki, M.
    Izumi, N.
    Sakamoto, N.
    Enomoto, N.
    Yatsuhashi, H.
    Kusakabe, A.
    Shinkai, N.
    Nojiri, S.
    Joh, T.
    Mizokami, M.
    JOURNAL OF VIRAL HEPATITIS, 2014, 21 (07) : 466 - 474
  • [25] Is there still a role for PEG IFN plus RBV therapy in patients with HCV genotype 1?
    Serfaty, Lawrence
    LIVER INTERNATIONAL, 2014, 34 : 11 - 12
  • [26] Mitochondrial effects of a 24-week course of pegylated-interferon (PEG-IFN) plus ribavirin (RBV) in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both
    Ballesteros, AL
    Miró, O
    López, S
    Fuster, D
    Videla, S
    Martínez, E
    Garrabou, G
    Salas, A
    Côté, H
    Tor, J
    Rey-Joly, C
    Planas, R
    Clotet, B
    Tural, C
    JOURNAL OF HEPATOLOGY, 2005, 42 : 199 - 199
  • [27] Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: Implications for treatment outcomes
    Dahari, Harel
    Affonso de Araujo, Evaldo S.
    Haagmans, Bart L.
    Layden, Thomas J.
    Cotler, Scott J.
    Barone, Antonio A.
    Neumann, Avidan U.
    JOURNAL OF HEPATOLOGY, 2010, 53 (03) : 460 - 467
  • [28] Predictive Factors for Silibinin Monotherapy in Patients With Chronic Hepatitis C and Nonresponse to PEG-IFN/RBV Therapy
    Rutter, Karoline
    Stattermayer, Albert
    Reiberger, Thomas
    Aberle, Judith H.
    Zinober, Kerstin
    Scherzer, Thomas-Matthias
    Beinhardt, Sandra
    Holzmann, Heidemarie
    Steindl-Munda, Petra
    Hofer, Harald
    Ferenci, Peter
    GASTROENTEROLOGY, 2010, 138 (05) : S214 - S215
  • [29] PREDICTIVE FACTORS FOR SILIBININ MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS C AND NONRESPONSE TO PEG-IFN/RBV THERAPY
    Rutter, K.
    Staettermayer, A.
    Reiberger, T.
    Aberle, J.
    Zinober, K.
    Scherzer, T. -M.
    Beinhardt, S.
    Holzmann, H.
    Steindl-Munda, P.
    Hofer, H.
    Ferenci, P.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S124 - S124
  • [30] Fluvastatin inhibits HCV replication in patients who do not respond to PEG-IFN therapy
    Nature Clinical Practice Gastroenterology & Hepatology, 2008, 5 (9): : 477 - 477